Your browser doesn't support javascript.
loading
Insulin Pump Therapy vs Multiple Daily Insulin Injections for Glycemic Control in Children With Type 1 Diabetes: A Systematic Review and Meta-Analysis.
Calderon Martinez, Ernesto; Castillo, Jaqueline L; Zachariah Saji, Stephin; Stein, Daniel; Khan, Tayyaba J; Guardado Williams, Rosa F; Munguía, Irma D; Arruarana, Victor Sebastian; Velasquez, Karen.
Afiliação
  • Calderon Martinez E; Digital Health, Universidad Nacional Autónoma de México, Mexico, MEX.
  • Castillo JL; General Medicine, Universidad Autonoma de Guadalajara, Guadalajara, MEX.
  • Zachariah Saji S; Graduate Medical Education, Our Lady of Fatima University, Valenzuela, PHL.
  • Stein D; General Medicine, St. George's University, St. George's, GRD.
  • Khan TJ; Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
  • Guardado Williams RF; General Medicine, National Autonomous University of Honduras, Tegucigalpa, HND.
  • Munguía ID; General Medicine, National Autonomous University of Honduras, Tegucigalpa, HND.
  • Arruarana VS; Internal Medicine, Brookdale University Hospital Medical Center, New York, USA.
  • Velasquez K; General Medicine, University of El Salvador, San Salvador, SLV.
Cureus ; 16(1): e52054, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38344584
ABSTRACT
Type 1 diabetes mellitus (T1DM), characterized by the autoimmune destruction of pancreatic beta cells and consequent insulin deficiency, leads to various complications. Management primarily focuses on optimal glycemic control through intensive insulin therapy, either via multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) using insulin pumps, which offer flexibility and improved basal insulin delivery. Despite the benefits of insulin pumps, such as reduced hypoglycemia risk and better mealtime insulin management, they pose challenges such as complexity in site changes and potential ketoacidosis due to tubing issues. This systematic review adheres to PRISMA guidelines and compares CSII with MDI in children and adolescents with T1DM, concentrating on outcomes such as glycemic control measured with HbA1c and glucose levels. The review includes studies meeting stringent criteria, encompassing a broad range of methodologies and geographies. The findings of this meta-analysis indicate the differences in glycemic control with CSII compared to MDI. However, significant heterogeneity in results and methodological variations across studies necessitate cautious interpretation. The study underscores the potential of CSII in offering better control for some patients, supporting a more personalized approach to T1DM management. It highlights the need for further research to understand the long-term effects and to refine treatment protocols, considering the variations in healthcare systems, treatment approaches, and patient demographics globally.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Systematic_reviews Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Systematic_reviews Idioma: En Ano de publicação: 2024 Tipo de documento: Article